Kim Kardashian’s Secret to Timeless Beauty: ‘Wigobi’ Diet Pill Unveils a Surprising Anti-Aging Benefit
Wigobi: The Diet Pill That Delays Aging and Reduces Mortality
- Presented at the European Society of Cardiology Conference: “Suppresses aging and reduces mortality by 19%”
Wigobi, a diet pill popular among overseas celebrities like Kim Kardashian and Tesla CEO Elon Musk, has been found to have an additional effect beyond its weight loss benefits. Research has shown that it can also delay aging, making it a highly sought-after treatment.
The British daily Guardian reported on the research results, which were announced at the European Society of Cardiology conference in London. The study found that Wigobi’s main ingredient, semaglutide, has a broader range of benefits than initially thought, including reducing the risk of arthritis, Alzheimer’s, cancer, and COVID-19, and lowering overall mortality rates.
Harlan Krumholz, a professor of medicine at Yale University School of Medicine who published the study results, stated, “Semaglutide has broader benefits than we first imagined. It’s not just about preventing heart attacks; it’s about improving health. It’s not surprising that when you improve people’s health in this way, you actually delay the aging process.”
The study, conducted by Novo Nordisk and an international research team including Harvard University, involved 17,604 participants aged 45 or older who were overweight or obese and had cardiovascular disease but no diabetes. The participants were divided into two groups: one that received semaglutide once a week and another that received a placebo. The results showed that the semaglutide group had a 19% lower mortality rate from all causes compared to the placebo group.
The researchers also found that the semaglutide group had improved heart failure symptoms and lower inflammation levels in the body, regardless of weight loss. Additionally, the semaglutide group was less likely to die from infections than the placebo group, and cardiovascular problems continued to decrease.
Semaglutide is a drug similar to the GLP-1 hormone secreted after a meal, which increases satiety and reduces appetite. GLP-1 is a hormone produced when food is consumed, and it lowers blood sugar levels, suppresses appetite in the gastrointestinal tract, and slows down the digestion of food.
Wigobi was approved by the U.S. Food and Drug Administration (FDA) in June 2021 as a prescription for weight loss (obesity treatment). According to Novo Nordisk’s clinical results, an average of 15% of body weight was reduced after 68 weeks with just one injection per week.
Tesla founder Elon Musk has also endorsed Wigobi, stating that it helped him maintain his figure. Although the price of the drug is expensive, around 1.8 million won (1,350 dollars) for a month, Wigobi is sold out worldwide.